The reality of drug pricing
By Andrew Willis | 01/03/19
High drug prices have been making headlines recently, with a recent U.S. Senate hearing into the matter earlier this week.
Should investors inject their portfolios with some pharma exposure to get behind this trend? Or are there dangerous side-effects to watch out for when getting behind companies selling thousand-dollar doses?
The industrial sector is experiencing a resurgence in 2024, fuelled by the three “Rs”: Recovery, Rebuilding, and Repatriation.
Harvest Portfolios Group Inc. (“Harvest”) announces that it will be terminating the…
Michael Kovacs explains why his firm has launched their first “balanced” ETFs, and why they’ve added an industrials product.
Harvest Portfolios Group Inc. (“Harvest”) declares the monthly cash distribution payable for Big Pharma Split Corp. of…
Harvest Portfolios Group Inc. (“Harvest”) announces the following distributions for Harvest ETFs…